Pacira Pharma (NASDAQ: PCRX) reported Q4 EPS of $0.91, $0.12 better than the analyst estimate of $0.79. Revenue for the quarter came in at $187.3 million versus the consensus estimate of $180.22 million.

GUIDANCE:

Pacira Pharma sees FY2025 revenue of $725-765 million, versus the consensus of $747.6 million.

For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.